Lamotrigine in mood disorders.
Lamotrigine is an anticonvulsant drug with good efficacy and safety in the treatment of epilepsy. There is now substantial evidence that lamotrigine is also useful in treating resistant depression, rapid cycling bipolar affective disorder, depressive episodes in bipolar affective disorder and in the maintenance phase or prophylaxis of bipolar affective disorder. There are possible roles in managing mood changes in borderline personality disorder, reducing chronic pain and treating schizoaffective disorder. The general range of doses found effective in affective disorders is from 50 to 300 mg daily. Clinical use seems to involve a titration of dose upwards over several weeks until the desired effect is obtained. However, further definitive double-blind, randomised controlled trials against gold standard treatments are required. Lamotrigine has a preferable side-effect profile compared to standard agents for bipolar affective disorder such as lithium or carbamazepine. Further research is certainly warranted and, given its tolerability, could point to lamotrigine as the treatment of choice for some affective disorders.
Green
Ben
B
Department of Psychiatry, University of Liverpool, UK. bengreen@liverpool.ac.uk
D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use; D018692:Antimanic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D000077213:Lamotrigine; D019964:Mood Disorders / Q000188:drug therapy*; D016896:Treatment Outcome; D014227:Triazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000700:Analgesics; D000927:Anticonvulsants; D000928:Antidepressive Agents; D018692:Antimanic Agents; D014227:Triazines; D000077213:Lamotrigine